BCCA Protocol Summary for Recurrent/Metastatic Salivary Gland cancers of the Head and Neck with Tamoxifen

Protocol Code	HNSAVTAM
Tumour Group	Head and Neck
Contact Physician	Dr. Cheryl Ho
ELIGIBILITY:ER positive or negative status	

- Recurrent malignancy for whom resection, radiotherapy or chemotherapy are no longer treatment options
- Current evidence based on case studies

TESTS:

Histologically confirmed recurrence of a salivary gland carcinoma

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Tamoxifen	20 mg PO once daily	PO

DISCONTINUE drug for severe side effects OR obvious progression of disease

PRECAUTIONS:

- 1. Women: hot flushes, vaginitis.
- 2. Men: decrease in libido, hot flushes.
- 3. Thromboembolism: Tamoxifen is associated with an increased risk of thromboembolism that is comparable to estrogen replacement therapy.

Contact Dr. Cheryl Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date Activated 1 Feb 2012

Date(s) Revised

REFERENCE

1. Elkin AD, Jacobs CD.Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. J Cancer Res Clin Oncol 2008;134:1151-3.

2. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngo Otol 1997; 111:1186-89.

BC Cancer Agency Protocol Summary HNSAVTAM

Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm